Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: James Lupski, Carlos Bustamante

Premium

James Lupski has been named a fellow of the American Academy of Arts and Sciences.

Lupski holds the Cullen Endowed Chair in Molecular Genetics at the Baylor College of Medicine, where he is also vice chair and professor of molecular and human genetics, and has played a leading role in the clinical implementation of chromosomal microarray analysis.

He has discovered several disease genes, including the first gene for Charcot-Marie Tooth syndrome, as well as the gene for the form of the disorder that affects him through next-generation sequencing. He holds a BS and PhD from New York University and an MD from New York University Medical School.


Carlos Bustamante has been named to the National Institutes of Health's Council of Councils, which advises the NIH Director on policies and activities of the Division of Program Coordination, Planning, and Strategic Initiatives.

Bustamante is a professor of genetics at Stanford University and co-founding director of the Stanford Center for Computational, Human, and Evolutionary Genomics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.